AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 17 - (NewsRx.com & NewsRx.net) -- Antisoma, Plc, (ASM) has been granted a U.S. patent for Therex, which is currently in Phase I studies for the treatment of breast cancer.
Therex is a naked humanized antibody that attaches itself to cancer cells. It helps components of the immune system, including natural killer cells, to find and destroy the cancer cells. The antibody recognizes MUC1, a cytokine-like receptor that is highly expressed by most solid tumors.
The U.S. patent covers antibodies that contain specified amino acid sequences and that recognize MUC1. The U.S. patent will provide protection to Therex until at least 2018.
Therex is initially being developed to treat women with breast cancer who have relapsed following first-line treatment.
"The granting of the U.S. patent for Therex is a further important strengthening of our intellectual ...